Cargando…

Whole-Body [(18)F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687

ACRIN 6687, a multi-center clinical trial evaluating differential response of bone metastases to dasatinib in men with metastatic castration-resistant prostate cancer (mCRPC), used [(18)F]-fluoride (NaF) PET imaging. We extend previous ACRIN 6687 dynamic imaging results by examining NaF whole-body (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muzi, Mark, O’Sullivan, Finbarr, Perk, Timothy G., Muzi, John P., Mankoff, David A., Jeraj, Robert, Duan, Fenghai, Yu, Evan Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167705/ https://www.ncbi.nlm.nih.gov/pubmed/33923126 http://dx.doi.org/10.3390/tomography7020013

Ejemplares similares

Assessment of the Prognostic Value of Radiomic Features in (18)F-FMISO PET Imaging of Hypoxia in Postsurgery Brain Cancer Patients: Secondary Analysis of Imaging Data from a Single-Center Study and the Multicenter ACRIN 6684 Trial
por: Muzi, Mark, et al.
Publicado: (2020)

Quantitation of Multiple Injection Dynamic PET Scans: An Investigation of the Benefits of Pooling Data from Separate Scans when Mapping Kinetics
por: Gu, Fengyun, et al.
Publicado: (2021)

Assessment of a statistical AIF extraction method for dynamic PET studies with (15)O water and (18)F fluorodeoxyglucose in locally advanced breast cancer patients
por: O’Sullivan, Finbarr, et al.
Publicado: (2017)

Effect of (18)F-FDG Uptake Time on Lesion Detectability in PET Imaging of Early-Stage Breast Cancer
por: Wangerin, Kristen A., et al.
Publicado: (2015)

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy
por: Ratai, Eva-Maria, et al.
Publicado: (2018)

Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of (18)F-Fluoride Metabolic Flux Than with Measurement of (18)F-Fluoride PET/CT SUV?
por: Azad, Gurdip K., et al.
Publicado: (2019)

Utility of SUV(max) on (18) F-FDG PET in detecting cervical nodal metastases
por: Lim, Rebecca S. M., et al.
Publicado: (2016)

PET AIF estimation when available ROI data is impacted by dispersive and/or background effects
por: O’Sullivan, Finbarr
Publicado: (2023)

Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV(max) in [(18)F]fluoride and [(18)F]FDG PET?
por: Azad, Gurdip K., et al.
Publicado: (2018)

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
por: Araujo, John C, et al.
Publicado: (2013)

SUVref: reducing reconstruction-dependent variation in PET SUV
por: Kelly, Matthew D, et al.
Publicado: (2011)

SUV variability in EARL-accredited conventional and digital PET
por: Koopman, Daniëlle, et al.
Publicado: (2019)

Is SUV Corrected for Lean Body Mass Superior to SUV of Body Weight in (68)Ga-PSMA PET/CT?
por: Aksu, Ayşegül, et al.
Publicado: (2021)

PSMA-PET Detection of Unusual Metastases in Castrate-Sensitive Prostate Carcinoma
por: Harris, Nathanial, et al.
Publicado: (2023)

Measurement of SUVs-Maximum for Normal Region Using VOI in PET/MRI and PET/CT
por: Park, Jeong Kyu, et al.
Publicado: (2014)

Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions
por: Pantel, Austin R., et al.
Publicado: (2022)

Correlation of (18)F-FDG/PET SUV(max), SUV(mean), MTV, and TLG with HIF-1α in Patients with Colorectal Cancer
por: Kaymak, Zümrüt Arda, et al.
Publicado: (2021)

Diagnostic classification of solitary pulmonary nodules using dual time (18)F-FDG PET/CT image texture features in granuloma-endemic regions
por: Chen, Song, et al.
Publicado: (2017)

FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements
por: Osman, Medhat M., et al.
Publicado: (2011)

Pulmonary Sequestration with Renal Aplasia and Elevated SUV Level in PET/CT
por: Şen, Serdar, et al.
Publicado: (2012)

Effect of Tumor-Pixel Positioning on the Variability of SUV Measurements in PET Images
por: Itagaki, Koji, et al.
Publicado: (2023)

Functional 4-D clustering for characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a prognostic biomarker for breast cancer
por: Chitalia, Rhea, et al.
Publicado: (2021)

Correction to: Functional 4-D clustering for characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a prognostic biomarker for breast cancer
por: Chitalia, Rhea, et al.
Publicado: (2021)

Using neighborhood gray tone difference matrix texture features on dual time point PET/CT images to differentiate malignant from benign FDG-avid solitary pulmonary nodules
por: Chen, Song, et al.
Publicado: (2019)

A Generalized Linear modeling approach to bootstrapping multi-frame PET image data
por: O’Sullivan, Finbarr, et al.
Publicado: (2021)

FDG-PET staging and importance of lymph node SUV in head and neck cancer
por: Kubicek, Gregory J, et al.
Publicado: (2010)

(18)F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with (223)Ra-chloride (Alpharadin)
por: Cook, Gary JR, et al.
Publicado: (2011)

Is it safe to drive SUVs?
Publicado: (1998)

Optimization of PET reconstruction algorithm, SUV thresholding algorithm and PET acquisition time in clinical (11)C-acetate PET/CT
por: Strandberg, Sara, et al.
Publicado: (2018)

Assessment of Mediastinal Tumors Using SUV(max) and Volumetric Parameters on FDG-PET/CT
por: Morita, Takahiro, et al.
Publicado: (2017)

Interobserver variability of image-derived arterial blood SUV in whole-body FDG PET
por: Hofheinz, Frank, et al.
Publicado: (2019)

Exploration of the threshold SUV for diagnosis of malignancy using (18)F-FBPA PET/CT
por: Isohashi, Kayako, et al.
Publicado: (2022)

Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor
por: Zwezerijnen, Gerben J. C., et al.
Publicado: (2022)

(18)F-fluorodeoxyglucose (FDG) PET or (18)F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study
por: Romine, Perrin E., et al.
Publicado: (2021)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study
por: Mattoni, Susanna, et al.
Publicado: (2022)

Relation between nodule size and (18)F-FDG-PET SUV for malignant and benign pulmonary nodules.
por: Khalaf, Majid, et al.
Publicado: (2008)

Deformation Effect on SUV(max) Changes in Thoracic Tumors Using 4-D PET/CT Scan
por: Huang, Tzung-Chi, et al.
Publicado: (2013)

Normal SUV Values Measured from NaF18- PET/CT Bone Scan Studies
por: Win, Aung Zaw, et al.
Publicado: (2014)

The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis
por: Leijenaar, Ralph T.H., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_oee11a09397pt2nqoo5lv2h87u